Expansion of the clinical and molecular spectrum of WWOX-related epileptic encephalopathy
- PMID: 36537114
- DOI: 10.1002/ajmg.a.63074
Expansion of the clinical and molecular spectrum of WWOX-related epileptic encephalopathy
Abstract
WWOX biallelic loss-of-function pathogenic single nucleotide variants (SNVs) and copy number variants (CNVs) including exonic deletions and duplications cause WWOX-related epileptic encephalopathy (WOREE) syndrome. This disorder is characterized by refractory epilepsy, axial hypotonia, peripheral hypertonia, progressive microcephaly, and premature death. Here we report five patients with WWOX biallelic predicted null variants identified by exome sequencing (ES), genome sequencing (GS), and/or chromosomal microarray analysis (CMA). SNVs and intragenic deletions of one or more exons were commonly reported in WOREE syndrome patients which made the genetic diagnosis challenging and required a combination of different diagnostic technologies. These patients presented with severe, developmental and epileptic encephalopathy (DEE), and other cardinal features consistent with WOREE syndrome. This report expands the clinical phenotype associated with this condition, including failure to thrive in most patients and epilepsy that responded to a ketogenic diet in three patients. Dysmorphic features and abnormal prenatal findings were not commonly observed. Additionally, recurrent pancreatitis and sensorineural hearing loss each were observed in single patients. In summary, these phenotypic features broaden the clinical spectrum of WOREE syndrome.
Keywords: WOREE syndrome; epilepsy; exon deletion; recurrent pancreatitis; sensorineural hearing loss.
© 2022 Wiley Periodicals LLC.
References
REFERENCES
-
- Abdel-Salam, G., Thoenes, M., Afifi, H. H., Körber, F., Swan, D., & Bolz, H. J. (2014). The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. Orphanet Journal of Rare Diseases, 9, 12. https://doi.org/10.1186/1750-1172-9-12
-
- Aldaz, C. M., & Hussain, T. (2020). WWOX loss of function in neurodevelopmental and neurodegenerative disorders. International Journal of Molecular Sciences, 21(23), 8922. https://doi.org/10.3390/ijms21238922
-
- Banne, E., Abudiab, B., Abu-Swai, S., Repudi, S. R., Steinberg, D. J., Shatleh, D., Alshammery, S., Lisowski, L., Gold, W., Carlen, P. L., & Aqeilan, R. I. (2021). Neurological disorders associated with WWOX germline mutations-a comprehensive overview. Cells, 10(4), 824. https://doi.org/10.3390/cells10040824
-
- Bednarek, A. K., Laflin, K. J., Daniel, R. L., Liao, Q., Hawkins, K. A., & Aldaz, C. M. (2000). WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Research, 60(8), 2140-2145.
-
- Ben-Salem, S., Al-Shamsi, A. M., John, A., Ali, B. R., & Al-Gazali, L. (2015). A novel whole exon deletion in WWOX gene causes early epilepsy, intellectual disability and optic atrophy. Journal of Molecular Neuroscience, 56(1), 17-23. https://doi.org/10.1007/s12031-014-0463-8
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
